EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma

Mingming Hu, Shuku Liu, Yi Han, Feng Wang, Yang Liu, Baohua Lu, Hongxia Li, Yuan Gao, Ying Wang, Wei Yang, Kang Shi, Bo Xiao und 6 weitere

MedComm · 2026-07 · 7 (7)

DOI: 10.1002/mco2.70793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 15.06.2026. Verfasst von Mingming Hu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Beijing Chest Hospital, Capital Medical University Beijing China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This phase II trial investigated perioperative camrelizumab plus neoadjuvant chemotherapy for patients with stage IIB–IIIB lung squamous cell carcinoma (LUSC) and explored predictive biomarkers of treatment response. Patients received neoadjuvant camrelizumab (200 mg, Day 1) in combination with nab‐paclitaxel (130 mg/m 2 , Days 1 and 8) and carboplatin (area under the curve = 5, Day 1) every 3 weeks for two cycles, followed by surgery and adjuvant camrelizumab for 1 year. The primary endpoint was major pathological response (MPR) rate. Forty‐five patients were treated, of whom 41 underwent surgery. Twenty‐seven of 45 patients (60.0%) achieved MPR and 20 (44.4%) achieved pathological complete response (pCR). With a median follow‐up of 37.5 months, the 3‐year disease‐free survival and overall survival rates were 65.9% and 68.7%, respectively. Among eight patients with stage IIIB disease, three (37.5%) achieved pCR. Baseline neutrophil percentage and smoking history were associated with MPR. T‐cell receptor (TCR) sequencing revealed that three V‐J gene pairs in TCR beta clones differed between the pCR and non‐pCR groups. This study supports the application of perioperative immunotherapy combined with neoadjuvant chemotherapy in patients with resectable locally advanced LUSC. The identification of blood biomarkers for precise patient selection warrants further in‐depth investigation.

Schlagwörter

Stichwörter der Autor:innen

camrelizumablung squamous cell carcinomamajor pathological responseneoadjuvant immunochemotherapyperioperative immunotherapy

Autor:innen und Institutionen

  • Department of Oncology Beijing Chest Hospital, Capital Medical University Beijing China.
  • Laboratory For Clinical Medicine Capital Medical University Beijing China.
  • Department of Thoracic Surgery Beijing Chest Hospital, Capital Medical University Beijing China.
  • Department of Pathology Beijing Chest Hospital, Capital Medical University Beijing China.

ORCID-Profile: Tongmei Zhang

Zitieren

APA

Hu, M., Liu, S., Han, Y., Wang, F., Liu, Y., Lu, B., Li, H., Gao, Y., Wang, Y., Yang, W., Shi, K., Xiao, B., Wang, Q., Du, J., Lin, H., Li, X., Wang, C., & Zhang, T. (2026). A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma. MedComm, 7(7). https://doi.org/10.1002/mco2.70793

Vancouver

Hu M, Liu S, Han Y, Wang F, Liu Y, Lu B, et al. A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma. MedComm. 2026;7(7). doi:10.1002/mco2.70793

BibTeX
@article{Hu2026,
  author = {Hu, Mingming and Liu, Shuku and Han, Yi and Wang, Feng and Liu, Yang and Lu, Baohua and Li, Hongxia and Gao, Yuan and Wang, Ying and Yang, Wei and Shi, Kang and Xiao, Bo and Wang, Qunhui and Du, Juan and Lin, Haifeng and Li, Xiaomi and Wang, Chong and Zhang, Tongmei},
  title = {A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {7},
  doi = {10.1002/mco2.70793}
}
Kostenlos starten →